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ABSTRACT
Background: Bleeding disturbances are the main complaint that cause most DMPA users discontinuing
contraceptive use. Mechanism underlying the bleeding disturbances is not clear. It is presumed that the condition
is related to fluctuation of estradiol level or to low persistent estradiol level
Objective: 1. To evaluate an association between bleeding pattern and estradiol level of DMPA users after 3, 6,
9, 12 months use. 2. To evaluate an association between estradiol level and length of use. 3. To evaluate an
association between bleeding pattern and estradiol level, body mass index (BMI), age, parity, total cholesterol
level of DMPA users.
Design: Observational study, secondary analysis nested on “Randomized Controlled Trial Planibu® and Depo
Progestin®”
Material and Method:  Seventy DMPA users received injection every 3 months for 12 months. Before injection
was administered, venous blood was taken and examination of estradiol level was done using Enzyme Imuno
Absorbent Assay (ELISA). In addition, in-depth interview was also done on bleeding pattern for the last reference
period (90 days). Subject was classified according to their bleeding pattern into groups of amenorrhea,
oligomenorrhea, spotting, and bleeding,
Results: All research subjects indicated low estradiol concentration with an average concentration less than
150 pg/ml. There was a correlation between length of usage and estradiol level; estradiol level after 12 months
of usage was less than 100 pg/ml. There was no different between bleeding pattern and estradiol in month 3, 6,
9,12  using bivariate analysis with t-test with amenorrhea group as reference and p > 0,05. T-test and Chi Square
analyses using amenorrhea group as reference stated that there was no association between bleeding pattern
and age, BMI, and parity. Using multivariate analysis with Multinomial Logistic Regression, it was stated that
correlation between estradiol concentration and bleeding pattern was not affected by age, body mass index, or
total cholesterol level. There was an association between bleeding pattern and cholesterol level using bivariate
and multivariate analyses.
Conclusion:  1. Estradiol level in various bleeding pattern after 3,6,9,12 month of usage was not different. 2.
There was correlation between low estradiol level and length of usage. 3. Association between bleeding pattern
and estradiol level was not influenced by age, parity and body mass index, and total cholesterol level.
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INTRODUCTION
Uterus bleeding are the complaint most found
on acceptor of DMPA injection contraception.
Bleeding disturbance is a side effect that mostly
results in acceptor that discontinues contraception
and the rate of the bleeding disturbance is 52-68%.1
Counseling is required by acceptor to prevent the
discontinuity of contraception usage considering that
side effect of bleeding disturbance is not harmful and
usually is only seen in first year of the usage that
will be better in next years.2
Mechanism or pathophysiology of irregular
bleeding on user of injection contraception is still
unclear. Many researhes mentioned that it was
because of fluctuating estradiol level or estradiol on
progesterone.  Other researches also mentioned that
it was because of low persistent estradiol level3-5.
Basic mechanism involved here is that cyclical
fluctuating estradiol or progesterone gave a stimulus
for endometrial growth and menstruation. Bleeding
disorder was caused by disturbaces in this cyclical
fluctuating level.6,7,8 Therapy bleeding disorder with
estradiol or progestin was based on this basic.
Others findings said that acceptors experience
amenorrhea had a low persistent estradiol level,
Estradiol level wasn’t different between amenorrhea
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or bleeding group. Estradiol level, estradiol receptor
level. and progesterone level wasn’t different between
amenorrhea and prolonged bleeding group.3,9 Another
research indicated that low persistent estradiol level
could be correlated with amenorrhea, spotting,
oligomenorrhea or prolonged bleeding.10
Based on that results, we need a study that
evaluate association between bleeding pattern and
estradiol level of depot medroxy progesterone acetate
users.
RESEARCH METHOD
This research used observational study design,
with secondary data analysis nested on research
“Double Blind Randomized Controlled Trial of
Planibu® and Depo Progestin®”. Primary research
was conducted in Purworejo regency and Manado
municipality from February 2006 to February 2007.
Population of primary research was married
women in reproductive age desiring to delay or space
pregnancy using injectable contraception in
Purworejo regency and Manado municipality. The
subject was women in childbearing age of 20-35
years old, being married, being healthy, being not
pregnant, still getting menstruation, and getting
injectable contraception of Planibu and Depo
Progestin according to random allocation received.
Subject of 70 women meeting inclusion and
exclusion criteria received DMPA injection every 3
months for 12 months given at the same time. Before
injection administration, vein blood was taken from
each acceptor and processed to be serum,
packaged, sent and examined its estradiol level in
laboratory according to standardized method.
Examination of estradiol level was done with
Enzyme-Linked Immunoabsorbent Assay (ELISA) by
an analyst in the Clinical Pathology Laboratory of
Dr. Sardjito Hospital in Yogyakarta. It was carried
out to prevent bias of measurement result.
Data on bleeding pattern was collected with in-
depth interview. The in-depth interview used familiar
and mutual-trust principles. Subject was required to
record menstrual pattern for last 90 days (referential
period) in menstrual diary chart previously given.
Subject that could not recall more than 10 days their
menstrual pattern in reference period were included
into exclusion criteria. It was to avoid recall bias. In-
depth interview on bleeding pattern was done before
injection. Subject was grouped into bleeding patterns:
amenorrhea, oligomenorrhea, spotting and bleeding.
In addition, monthly regular visit was done for
counseling and preventing drop-out.
Bleeding group included frequent and prolonged
bleeding. Oligomenorea group included infrequent
and reguler bleeding. Spotting group included
subjects experience bleeding and spotting pattern.
Amenorea included subjects didn’t experience
bleeding and spotting pattern. Frequent bleeding is
defined as subjects experience  more than 4
episodes of bledings. Prolonged bleeding is defined
as one episode of bleeding lasting more than 10
days. Irreguler bleeding is defined as bleeding free
interval less than 17 days. Reguller bleeding is
defined as bleeding free interval more than 17 days.
Spotting is defined as  subjects didn’t need sanitary
napkins. Reference period is defined as 90 days like
WHO standard.
RESULT AND DISCUSSION
Characteristic of each research group was
homogenous (Table 1). So, it was expected that
difference between variables that was seen in this
research was not due to characteristic difference of
each group of bleeding pattern as a dependent variable.
Table 1. Characteristic of research subject in month 12
Variable  Amenorrhea  Oligomenorrhea  Spotting  
BMI (kg/m
2
) (Mean) 23.39 20.97 23.84 
 (SD) 3.58 3.02 4.02 
Age (year) (Mean) 28 31 29 
 (SD) 5 5 5 
Cholesterol (mg/dl) (Mean) 165.27 136.85 139.34 
 (SD) 37.07 24.91 35.57 
Estradiol (pg/ml) (Mean) 94.03 91.33 97.77 
 (SD) 15.88 12.34 14.13 
Parity      
1  23(42.6%) 2(25%) 2(25%) 
2-3  28(51.9%) 5(62.5%) 6(75%) 
≥4  3(5.6%) 1(12.5%)  
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The result indicated that there occurred change
in bleeding pattern on DMPA acceptors over time.
Therefore, with longer contraception use, dominant
bleeding pattern shifted from irregular and spotting
bleeding to be amenorrhea (Table 3). Discontinuity
rate will decrease over time because in the past 20
years, there have been changes in people’s opinion
about importance of monthly menstruation. Most
acceptors were more comfortable with oligo/
amenorrhea condition compared with irregular or
regular bleeding monthly. It was related to their
sexual, social or religious activities.11,12
Entirely, estradiol level in the research subject
was low with average level less than 130 pg/ml, while
after 12-month use, estradiol level decreased to be
<100 pg/ml (Table 3). The suppressed estradiol level
suited follicular phase of menstrual cycle. Estradiol
suppression agreed with previous research where
concentration of estradiol on DMPA acceptor was
low and kept beyond menopause women (<100 pg/
ml).13,14 The research found estradiol level closing
one in menopause women compared with follicular
phase (18.9 pg/ml). It might be due to its reagent
that has better sensitivity at low estradiol level.15
There was no association between bleeding
pattern and age, parity, BMI (Table 2). It was also
suggested in previous publications.9,15 They
presented that there is an inverse association
between estradiol and duration of contraception
usage, but there is not found association between
estradiol level and age, body mass index, parity and
existence of uterus bleeding. There was difference
in cholesterol level between amenorrhea group and
oligomenorrhea group (p=0.04).
Estradiol suppression was more significant with
longer contraception usage (Table 3). For example,
in amenorrhea group, there occur estradiol decrease
from 134.420 in month 3, to 107.843 pg/ml, 100/898
pg/ml, 94.029 pg/ml in month 6, 9, and 12. The similar
thing also occurred in oligomenorrhea and spotting
group. Previous research also indicated that there
was a reverse association between estradiol level
and duration of use of DMPA contraception.10,15
Estradiol level in various bleeding patterns was
not different on month 3, 6, 9, and 12. Estradiol level
Table 2. Bivariate analysis: association of bleeding pattern and BMI, age, cholesterol level and parity
Table 3. Bivariate analysis: association of bleeding pattern and estradiol level in month 3, 6, 9, and 12
T-test 
 Amenorrhea* Oligomenorrhea Spotting 
 Mean SD Mean SD T value Sig/p Mean SD T value Sig/p 
BMI  (kg/m
2
 23.9 3.58 20.97 3.02 -1.82 0.07 23.84 4.02 0.33 0.75 
Age (year) 28.20 4.83 30.88 4.76 1.46 0.15 29.25 5.12 0.57 0.57 
Cholesterol (mgdl) 165.27 37.07 136.85 24.91 -2.09 0.04 139.34 35.57 -1.85 0.07 
* Reference     Significant: p<0.05 
 
Chi-Square 
Amenorrhea Oligomenorrhea Spotting  
N % N % N % 
X
2 
Sig/p 
 Parity 1 23 (42.6) 2 (25.0) 2 (25.0) 2.839 0.585 
2-3 28 (51.9) 5 (62.5) 6 (75.0)   
≥4 3 (5.6) 1 (12.5) 0 (0)   
Significant: p<0.05 
 
T-test 
Estradiol level 
Month Bleeding pattern 
Mean SD 
t value Sig/p 
3 Amenorrhea* 134.420 18.696   
 Oligomenorrhea  129.620 15.613 -0.629 0.533 
 Spotting  133.743 8.829 -0.085 0.934 
 Bleeding  130.225 13.194 -0.587 0.563 
6 Amenorrhea* 107.843 14.33   
 Oligomenorrhea  112.531 7.607 1.234 0.223 
 Spotting  107.554 16.232 -0.057 0.954 
9 Amenorrhea* 100.898 11.273   
 Oligomenorrhea  97.177 17.844 0.895 0.375 
 Spotting  100.564 8.127 0.087 0.931 
12 Amenorrhea* 94.029 15.88   
 Oligomenorrhea  91.333 12.34 -0.457 0.649 
 Spotting  97.769 14.13 0.590 0.558 
* Reference           Significant: p<0.05 
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in amenorrhea, oligomenorrhea, spotting or bleeding
groups was not different to each other (Table 3).
Bivariate analysis to view association was done with
t-test using amenorrhea as reference. There was no
association between estradiol level and bleeding
pattern with p more than 0.05.
Multivariate analysis with multinomial logistic
regression was done to view influence of body mass
index, age, and total cholesterol level on association
of bleeding pattern and estradiol level. The
association between bleeding pattern and estradiol
level after making control over age, BMI, total
cholesterol factors was not found (Table 4). There
was different cholesterol level between amenorrhea
group and spotting group (p=0.03).
It showed that there was an association
between bleeding pattern and cholesterol level that
was consistent whether it used univariate, bivariate
or multivariate analysis. In univariate analysis, the
significance level was 0.03 (p=0.03); in bivariate
analysis between amenorrhea group and
oligomenorrhea group, the significance level was 0.04
(p=0.04); and in multivariate analysis between
amenorrhea group and spotting group, the
significance level was 0.03 (p=0.03) (Table 1, 2, 3).
Ester cholesterol is precursor of steroid hormone
and, cholesterol level will affect synthesis of endogen
estradiol. It is known that increasingly suppressed
and low estradiol level will result in change in bleeding
pattern from irregular/spotting to be amenorrhea, so
that low cholesterol intake may reduce endogen
estradiol synthesis and decrease frequency of
irregular bleeding/spotting. In addition, it is also
known that cholesterol is one of important
substances making up cell membrane determining
integrity of cell membrane and vascular. Cholesterol
is made up from nuclear ring system with
hydrocarbon chain and has a main characteristic of
amphipathic (hydrophobic and hydrophilic).16
Mechanism related to endometrial bleeding in DMPA
acceptor was endometrial vascular morphology,
changes in vascular structure integrity, perfusion and
endometrial oxygenation change, changes in
endometrial response to steroid hormone, changes
in endometrial vascular hemostasis and changes in
immunocompetent cell.3
No association of bleeding pattern and estradiol
level was also presented by other research indicating
that estradiol level, estradiol receptor level and
progesterone receptor level were not different in
amenorrhea group and bleeding group. This research
has similar methodology where blood sample and
endometrial biopsy were done once in end of reference
period.9
Bleeding mechanism on DMPA contraception
acceptor may be due to fluctuation of estradiol and/
or progesterone or persistent low estradiol level
resulting in bleeding through progesterone
breakthrough bleeding mechanism. Acceptor with
amenorrhea underwent persistent low estradiol level
that then fluctuated near menstruation.3,11
Other research stated that low estradiol level
might relate to period of amenorrhea,
oligomenorrhea, spotting or bleeding. It indicated that
association between bleeding pattern and estradiol
level was unclear; bleeding may occur or stop without
any change in estradiol level. Existence of various
bleeding patterns and low estradiol level indicate no
Table 4. Multivariate analysis with multinomial Logistic regression: association of bleeding pattern and
estradiol level by controlling BMI, age, total cholesterol factors in month 12
Dependent variable: bleeding pattern*
 
95% CI 
Variable X
2
 Wald Sig/p OR 
Lower Upper 
- Oligomenorrhea Independent      
 Estradiol 0.030 0.862 0.995 0.939 1.054 
 Age 2.614 0.106 1.183 0.965 1.449 
 BMI 3.094 0.079 0.750 0.545 1.033 
 Cholesterol  2.543 0.111 0.975 0.945 1.006 
- Spotting Independent      
 Estradiol 0.826 0.363 1.032 0.964 1.105 
 Age 0.179 0.672 1.039 0.869 1.243 
 BMI 0.000 0.987 0.997 0.724 1.374 
 Cholesterol  4.686 0.030 0.967 0.938 0.997 
* Reference: amenorrhea     Significant: p<0.05 
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association between bleeding pattern and estradiol
level.10,17,18 No association between bleeding pattern
and estradiol level is confirmed by other findings in a
longitudinal study where women with the same
hormonal condition may undergo different bleeding
patterns. For example, low estradiol level and no
luteal activity may cause amenorrhea, frequent
bleeding, and prolonged bleeding. In contrary, women
with regular bleeding may have ultrasonography
image and estradiol and progesterone levels that
agree with one in normal ovulation, luteinization,
unruptured follicle, growing follicle without ovulation,
and no growing follicle.19
Contradiction was presented by other research
suggesting that prolonged bleeding, oligomenorrhea
condition, or end period of amenorrhea were marked
with the increase in estradiol level which was then
followed by the decrease in estradiol level. Result of
this research was supported by other research
stating that the decrease in estradiol level happened
in 72 hours before withdrawal bleeding occurred20.
Other researchers stated that an incident of bleeding
after increase in, which was followed by decrease
in, estradiol level is found in long term injection
contraception acceptor or Noretindrone enantat
groups.19
In two other studies, one in Norplant acceptor3
and another in Nestorone10, Faudner et al stated that
fluctuation of estradiol level did not influence bleeding
pattern. Bleeding occur after increase in, which was
followed by decrease in, estradiol or estradiol and
progesterone levels. Bleeding period often started
with decrease in estradiol level and end with increase
in estradiol level3,21. Irregular bleeding was not always
related to fluctuating estradiol level. It is supported
with other research stating that subject with irregular/
frequent bleeding had persistent low estradiol level
(<75pg/ml) without luteal activity and bleeding might
occur without estradiol fluctuation.3,15 On Nestorone
acceptor, in anovulation cycle, duration of bleeding
significantly was related directly to the highest
estradiol level at previous 15 day.10
Lockwood et al22 did a research by taking
endometrial sample from bleeding location on women
using DMPA and found that level of Tissue Factor
(TF), an early initiator of homeostasis, decreased at
the site and found a reduced level of estrogen and
progesterone receptor at the site. Research taking
endometrial sample at the same location in bleeding
and not bleeding episode is still required. Other
research indicated that there was no difference of
estrogen and progesterone receptor level between
amenorrhea and bleeding groups9.
Other researches indicated that bleeding during
the use of DMPA injectable contraception was related
to condition of increase in and decrease in estradiol
level or was related to persistent low estradiol level.
Mechanism underlying bleeding at low estradiol level
is progesterone breakthrough bleeding3. Both
different hormonal conditions may relate to normal
cycle condition, oligomenorrhea, amenorrhea,
irregular/frequent bleeding or prolonged bleeding3.
No association between bleeding pattern and
estradiol level in this research might be due to some
factors. First, pathophysiology of various researches
stated that bleeding occurred due to fluctuation of
estradiol and/or progesterone, while in amenorrhea
estradiol level was persistently low till then fluctuated
near menstruation. Therefore, it was possible that
measurement of estradiol was done while it could
not capture the changes. Single/infrequent
measurement could not capture estradiol variability.
Level of hormone suppression depended on time of
sample taking15. Both bleedings occurred due to
mechanism of progesterone breakthrough bleeding
where persistent low estradiol level due to estradiol
suppression was not equal to high progesterone
condition3.
Mechanism underlying effect of estradiol on
endometrial bleeding is not clear. Some opinions
suggest that it relate to histological change of
endometrium or endometrial thickness measured
with ultrasonography and change in vascular
endometrium9. In Norplant acceptor, thin endometrium
was found, which was not related to bleeding pattern
and estradiol and progesterone levels. Some
researchers reported positive association between
endometrium thickness, peripheral estradiol level and
amount of bleeding day in period of 90 days before
endometrium biopsy. A study done for 18.5 years on
Norplant acceptor by Darney et al6 found that
proliferative endometrium was related to abnormal
bleeding.
In this research, a three-month period of free
contraception before using injectable contraception
was used to avoid loss of exogenous hormonal effect
in acceptor blood. Washing period was determined
3 months according to washing period suggested
by WHO.
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A one month follow up period in early research
agreed with recommendation. A period of one month
is important to: (1) record information on service
quality, (2) provide additional data on socio-
demography, and (3) record side effects due to use
of injecTable contraception.
CONCLUSION
There is no association between bleeding pattern
and estradiol level after 3, 6, 9, and 12 months of
use of DMPA injectable contraception. Estradiol level
will decrease with longer time of use of contraception
which suppressed estradiol level. An association
between bleeding pattern and estradiol level is not
influenced by age, parity, BMI and total cholesterol
level
SUGGESTION
Further research with greater samples that
measure estradiol level in a series of ways to see
existence of fluctuation of estradiol level underlying
mechanism of bleeding in DMPA acceptor is required.
To understand progesterone breakthrough bleeding
as mechanism underlying uterus bleeding on DMPA
acceptor, a series of measurement of progesterone
level is required.
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